The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Viral Hepatitis B — Treatment Indications

Evidence-based criteria for initiating antiviral therapy in chronic hepatitis B based on viral load, transaminases, fibrosis, and special populations.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Internal Medicine department. Book Appointment →

What is Viral Hepatitis B — Treatment Indications?

Chronic hepatitis B (CHB) is HBsAg-positivity for >6 months. Disease evolves through immune-tolerant, immune-active (HBeAg-positive or HBeAg-negative chronic hepatitis), inactive carrier, and reactivation phases. Treatment indications integrate HBV DNA, ALT, HBeAg status, liver fibrosis assessment (FibroScan or biopsy), and special clinical situations.

Major guidelines (AASLD, EASL, APASL, Turkish Ministry of Health) converge on key indications: HBV DNA >2,000 IU/mL with ALT > upper limit of normal and significant fibrosis (≥F2) or inflammation; cirrhosis at any HBV DNA; HBeAg-positive immune-active patients with persistent ALT elevation; reactivation in immunosuppression or chemotherapy; pregnancy with high viral load (>200,000 IU/mL) for prevention of mother-to-child transmission; HBV-HIV coinfection (treat both); HBV-HCV or HBV-HDV; family history of HCC; extra-hepatic manifestations (glomerulonephritis, polyarteritis nodosa, cryoglobulinemia); post-liver-transplant prophylaxis.

First-line oral antivirals are entecavir 0.5 mg/day, tenofovir disoproxil fumarate 300 mg/day, and tenofovir alafenamide 25 mg/day; the latter has better renal and bone safety. Pegylated interferon-alfa is finite-duration alternative for selected HBeAg-positive patients with high ALT, low DNA, and good predictors. Treatment is generally indefinite, with stopping rules (HBsAg seroclearance, sustained off-therapy response in selected HBeAg-negative patients) under research. Monitoring includes HBV DNA, ALT, AFP, ultrasound for HCC surveillance every 6 months in cirrhotics and high-risk groups, renal function, bone health on tenofovir, and resistance testing if breakthrough.

Symptoms

Often asymptomatic in chronic phase
Fatigue
Right upper quadrant discomfort
Anorexia, nausea
Jaundice in active hepatitis or flare
Pruritus, dark urine in flare
Hepatomegaly
Splenomegaly in cirrhosis
Spider angiomata, palmar erythema (cirrhosis)
Ascites, encephalopathy (decompensated cirrhosis)
Variceal bleeding (decompensation)
Hepatocellular carcinoma symptoms (weight loss, abdominal pain)
Extra-hepatic: arthralgia, glomerulonephritis, vasculitis
Reactivation flare in immunosuppression (severe hepatitis, jaundice)
Asymptomatic ALT elevation found on screening

Risk Factors

HBV DNA >2,000 IU/mL with ALT elevation
HBV DNA >20,000 IU/mL with HBeAg positive (immune-active)
Compensated or decompensated cirrhosis at any HBV DNA
Significant fibrosis ≥F2 by FibroScan or biopsy
Hepatocellular carcinoma history
Family history of HCC or cirrhosis
HBV-HIV, HBV-HCV, HBV-HDV coinfection
Immunosuppression: chemotherapy, rituximab, anti-TNF, transplant, corticosteroids
Pregnancy with HBV DNA >200,000 IU/mL (third trimester)
Extra-hepatic manifestations: glomerulonephritis, polyarteritis nodosa, cryoglobulinemia
Acute liver failure due to HBV
HBeAg-negative chronic hepatitis with HBV DNA >2,000 IU/mL and ALT elevation
Persistent or fluctuating ALT > upper limit of normal
Age >40 with elevated ALT and HBV DNA >2,000
Healthcare workers with significant viremia per institutional policy

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • New HBsAg positivity
  • Elevated ALT and known HBV
  • Pregnancy with HBV positive (third trimester planning)
  • Cancer chemotherapy or biological therapy with HBsAg or anti-HBc positivity
  • Liver or other organ transplant evaluation with HBV
  • Family history of HCC with chronic HBV
  • HBV-HIV, HBV-HDV coinfection
  • Reactivation symptoms in immunosuppression
  • Cirrhosis or HCC suspicion
  • Extra-hepatic manifestations (proteinuria, vasculitis)

Treatment Methods

01
Confirm HBsAg positivity for >6 months (chronic infection)
02
Initial workup: HBeAg, anti-HBe, HBV DNA quantification, ALT, AST, bilirubin, albumin, INR, CBC, AFP, HIV, HCV, HDV (in HBsAg+)
03
Liver fibrosis assessment: FibroScan, biopsy, or non-invasive scores (APRI, FIB-4)
04
Abdominal ultrasound for HCC surveillance every 6 months in cirrhotics, family history, Asian men >40, women >50
05
Identify treatment indication per HBeAg status, viral load, ALT, fibrosis, special conditions
06
First-line antivirals: entecavir 0.5 mg/day, tenofovir disoproxil 300 mg/day, or tenofovir alafenamide 25 mg/day
07
Pegylated interferon-alfa 180 mcg/week for 48 weeks in selected HBeAg-positive patients with favorable predictors (high ALT, low DNA, female, genotype A)
08
Pregnancy with HBV DNA >200,000 IU/mL: tenofovir disoproxil from 28-32 weeks gestation through delivery; infant immunoprophylaxis (HBIG + vaccine)
09
Immunosuppression / chemotherapy: prophylactic entecavir or tenofovir before and during therapy; continue 6-12 months after biological therapy or anti-CD20
10
HIV-HBV coinfection: tenofovir-containing antiretroviral regimen treating both viruses
11
HDV coinfection: pegylated interferon-alfa, bulevirtide where available
12
Cirrhosis: lifelong antiviral, HCC surveillance, varices screening, vaccination (hepatitis A, pneumococcal, influenza)
13
Monitor: HBV DNA every 3-6 months on therapy until undetectable, then 6-12 months; ALT, renal function (especially on tenofovir disoproxil), bone density
14
Resistance testing if virologic breakthrough on treatment
15
Adherence counseling, drug-drug interactions, alcohol cessation, hepatitis A vaccination
16
Family screening of household contacts and sexual partners; vaccinate susceptible contacts
17
Pregnancy planning, contraception, fertility counseling
18
HCC surveillance with ultrasound + AFP every 6 months in cirrhotics and high-risk groups
19
Treatment discontinuation considered selectively in HBeAg-positive after seroconversion (with consolidation) or in HBeAg-negative with HBsAg loss
20
Multidisciplinary care: hepatology, infectious disease, obstetrics, oncology, transplant team
21
Patient education on chronic disease, vaccination of contacts, transmission prevention, lifestyle

Which Department to Visit?

You can visit our Enfeksiyon Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Enfeksiyon Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Flu (Influenza)

Enfeksiyon Hastalıkları

Influenza is a seasonal contagious respiratory disease caused by influenza viruses; it presents with high fever, muscle pain, and severe fatigue.

COVID-19

Enfeksiyon Hastalıkları

COVID-19 is a contagious disease caused by the SARS-CoV-2 coronavirus with a wide clinical spectrum ranging from asymptomatic to severe pneumonia.

Upper Respiratory Tract Infection

Enfeksiyon Hastalıkları

Upper respiratory tract infections are diseases that include common cold, pharyngitis, sinusitis, and laryngitis, often of viral origin and self-limited.

Urinary Tract Infection

Enfeksiyon Hastalıkları

Urinary tract infections are common bacterial infections most often caused by Escherichia coli, presenting with burning and frequent urination.

Hepatitis A (HAV)

Enfeksiyon Hastalıkları

Hepatitis A is an acute, self-limited liver infection transmitted via the fecal-oral route causing acute hepatitis without chronicity; supportive care suffices in most cases, while vaccination prevents outbreaks and post-exposure prophylaxis within 2 weeks is effective.

Hepatitis B

Enfeksiyon Hastalıkları

Hepatitis B is a contagious infection caused by HBV virus transmitted via blood, sexual intercourse, and mother-to-child, that can become chronic and progress to cirrhosis and liver cancer.

Hepatitis C

Enfeksiyon Hastalıkları

Hepatitis C is a liver disease caused by HCV virus transmitted mainly by blood; the rate of chronicity is high, but cure is possible with new antiviral drugs.

HIV/AIDS Information

Enfeksiyon Hastalıkları

HIV is a virus that targets the immune system; if untreated, it progresses to AIDS. With modern antiretroviral therapy, HIV-positive individuals can lead healthy, long lives.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.